SCHEMBL13376352

SCHEMBL13376352

Cc1ccc(N)cc1-c1cc2cnc(Cl)cc2n(-c2ccccc2)c1=N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GRM5 P41594 1/20 0.35
TDP2 O95551 1/20 0.33
FGFR1 P11362 2/20 0.32
SRC P12931 1/20 0.31
MAT2A P31153 2/20 0.31
CDC7 O00311 1/20 0.31
CDK2 P24941 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
BRD4 O60885 1/20 0.31
BTK Q06187 1/20 0.31
AOC3 Q16853 1/20 0.31
DCTPP1 Q9H773 1/20 0.31
CYP3A4 P08684 1/20 0.31
PI4KA P42356 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13376335 0.89 ALDH1A1 (0.42) PLA2G7ALDH1A1GRM5FGFR1SRC
SCHEMBL501865 0.88 PLA2G7 (0.41) PLA2G7ALDH1A1GRM5TDP2FGFR1
SCHEMBL502067 0.76 ALDH1A1 (0.41) PLA2G7ALDH1A1GRM5TDP2FGFR1
SCHEMBL502110 0.74 SRC (0.51) PLA2G7ALDH1A1FGFR1SRCCDC7
SCHEMBL5061783 0.74 BTK (0.49) SRCBTK
SCHEMBL25983851 0.70 PLA2G7 (0.54) PLA2G7ALDH1A1GRM5MEN1MAPT
SCHEMBL15289630 0.70 PLA2G7 (0.44) PLA2G7ALDH1A1GRM5FGFR1SRC
SCHEMBL17119663 0.69 BTK (0.48) TDP2SRCBTKCYP3A4
SCHEMBL4426075 0.65 BTK (0.46) ALDH1A1GRM5TDP2FGFR1SRC
SCHEMBL5046332 0.65 SRC (0.51) FGFR1SRCCDC7CDK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC PLA2G7 3060/4885ALDH1A1 4274/4885GRM5 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.